in your analyses, do not always comment on the full stack, except where relevant.

The short version: the retrieved evidence does not test contrast agents with your four-drug regimen, so the additive renal risk you flagged is a plausible mechanism, not a tested finding.

The evidence block contains no study of CT or MRI contrast agents combined with clonazepam, mirtazapine, gabapentin, and olanzapine. What it does contain is a study of iopentol, an iodinated contrast agent, in patients with advanced chronic renal failure [2]. That study found iopentol did not change glomerular or tubular function in those patients, but its elimination was delayed, with detectable levels persisting up to 5 days [2]. In patients with severely impaired kidneys, plasma iopentol clearance was 40% higher than renal clearance, meaning extrarenal routes (likely fecal) compensated [2].

Your concern about additive effects is specific and well-targeted. Gabapentin is excreted renally unchanged [1]. In a geriatric patient with reduced kidney function, gabapentin accumulates, raising sedation and fall risk. Adding a contrast agent that also lingers in the body when kidneys are slow [2] means both drugs stay longer than expected. The concern is not a direct chemical interaction but a shared bottleneck: the kidneys.

The evidence does not test this combination. No study in the retrieval gave a geriatric patient these four drugs plus a contrast agent and measured outcomes. The iopentol study [2] is the closest match, and it found no acute renal injury from the contrast agent alone in patients with advanced renal failure. But that study did not add gabapentin or the other three drugs. The additive sedation risk from the four-drug regimen (clonazepam at GABA-A, mirtazapine at H1, olanzapine at H1, gabapentin at calcium channels) is the primary concern, and the contrast agent does not change that calculus.

My call: the additive renal risk you flagged is mechanistically plausible but untested in the retrieved evidence. The main risk from this combination in a geriatric patient is additive CNS depression, not a contrast-agent interaction. Confidence: low, because the evidence does not study the question.